Introduction

Full (4.05 min) version of the video click here

Summary (2.52 min) version of video click here

 

The global value of generic, biosimilar and value added medicines

For the first time, Medicines for Europe and IGBA joined forces to create an opportunity to learn about global developments in generic, biosimilar and value added medicines. Our joint 22nd Medicines for Europe and 19th IGBA Annual Conference delivered a unique platform for you to meet and network with industry, regulators and key stakeholders from all over the world.

At the 2016 Conference in Dubrovnik, attendees had the opportunity to:
* Discover new strategic business opportunities
* Gain insight into the latest market developments
* Discuss sustainable healthcare systems with payers, regulators and policy makers

Last year’s EGA Annual Conference in Berlin was attended by 250 delegates representing more than 190 companies and organisations from over 30 different countries worldwide. 

You can follow the event on Twitter #IGBAEGA2016

Who attended

  • International Generic and Biosimilar Medicines Industry
  • National, European and International Authority Representatives
  • Pharmaceutical Sector Analysts and Consultants
  • Investment Bankers
  • Pharmaceutical Wholesalers
  • Consultants and Service Providers
  • API Manufacturers
  • Law Firms – Patent Litigation Specialists
  • Pharmaceutical Distributors
  • Academia
  • Healthcare Professionals
  • Health Insurers
  • Medical Societies
  • Patient Organisations

With the participation of

WHAT DELEGATES SAID ABOUT THE EGA 2015 EDITION

“This is the forum where we shape our industry”
Nick Haggar, EGA President

LIST OF COMPANIES AND ORGANISATIONS PRESENT IN THE EGA EVENT 2015

CONFERENCE FLYER

CHAIRPERSONS AND SPEAKERS


Jacek Glinka
President, Medicines for Europe - President Europe, Mylan

Vivian Frittelli
Chairman, IGBA - Chief Executive, National Association of Pharmaceutical Manufacturers (NAPM)

Vytenis Andriukaitis
Commissioner, European Commission DG SANTE

Belinda Wood
CEO, Generic and Biosimilar Medicines Association (GBMA), Australia

Simon Goeller, Dr.
Partner, McKinsey & Company, Inc.

Michael Dilger
Partner, Simon-Kucher & Partners

Emer Cooke
Head of International Affairs, EMA

Pierluigi Antonelli
Head of Western Europe, Sandoz

Heather Bresch
Chair, Generic Pharmaceutical Association (GPhA) - CEO, Mylan NV

Annie Pannelay
Principal, EIU Healthcare

Prof. Mondher Toumi
CEO, Creativ-Ceutical

Christoph Stoller
Senior Vice President Generics and Commercial Operations Europe, Teva - Vice-President, Medicines for Europe

Martin Albert
Head of Portfolio & Program Management, Sanofi Generics

About the IGPA now IGBA

The International Generic and Biosimilar Medicines Association (IGBA) was founded as IGPA (International Generic Pharmaceutical Alliance) in March 1997 to strengthen cooperation between associations representing manufacturers of generic medicines. Its membership includes the Medicines for Europe (formerly EGA – Europe), the CGPA (Canada), the GPhA (USA), the JAPM (Jordan), the NAPM (South Africa), the TGPA (Taiwan) and the JGA (Japan) while the associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI) are Associate Members. The IGBA is at the forefront of stimulating competitiveness and innovation in the pharmaceutical sector by providing high quality pro-competitive medicines to millions of patients around the world. Through its constituent member associations, the IGBA maintains constant dialogue with government authorities (including the European Commission for Europe) as well as with international institutions such as WTO, WIPO and WHO. More information: www.igbamedicines.org

MEDIA PARTNERS AND SPONSORS